A Clinical Trial to Assess Safety and Efficacy of Daratumumab in the Treatment of Primary Immune Thrombocytopenia

NCT05562882 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Immune Thrombocytopenia

Interventions

DRUG: Daratumumab Injection

Sponsor

Institute of Hematology & Blood Diseases Hospital, China